NCT00843882 2026-03-18
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
29 trialsNCT00310232 2024-04-02
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Ontario Clinical Oncology Group (OCOG)
Phase 3 Terminated
NCT00060398 2023-06-15
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00028938 2021-09-09
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 3 Completed
NCT00004917 2020-10-22
Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00070382 2020-08-03
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
Jonsson Comprehensive Cancer Center
Phase 3 Completed
NCT00254436 2018-10-25
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00656448 2018-05-30
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00338286 2018-03-19
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00711958 2017-09-05
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
Sandoz
Phase 3 Completed
NCT00017004 2017-08-09
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
GOG Foundation
Phase 3 Completed
NCT00058331 2016-07-18
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00482716 2014-01-10
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00003341 2013-07-03
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00148421 2013-05-15
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Amgen
Phase 3 Completed
NCT00017277 2012-09-24
Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00210587 2011-06-10
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00210730 2011-06-10
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00341055 2011-06-10
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00261677 2011-05-23
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
Ortho Biotech Products, L.P.
Phase 3 Completed
NCT00246597 2011-05-19
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00350090 2011-05-19
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00270101 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00270127 2011-05-18
Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00270166 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00083434 2011-04-27
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00083486 2011-04-27
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00211133 2010-11-30
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00364455 2010-04-27
Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
Janssen-Ortho Inc., Canada
Phase 3 Completed